Beta Bionics, Inc. Common Stock

Beta Bionics announced a partnership with Senseonics to expand compatibility between its automated insulin delivery platform and Senseonics' continuous glucose monitoring technology. The integrated iLet and Eversense 365 system is expected to launch commercially in the fourth quarter of 2026, after which the iLet is expected to support Dexcom G6, Dexcom G7, Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365, which Beta Bionics expects will make the iLet compatible with more CGM manufacturers than any other AID system. Beta Bionics also intends to integrate its next-generation mint AID system with Eversense 365 in the future. Following the Sept. 22 announcement, shares of BBNX lost more than 8% in the next trading session and have lost 32.6% year to date, compared with the industry's 4.9% decline, leaving the company with a market capitalization of $967.7 million. Separately, BBNX recently secured FDA clearance for its Mint patch pump and unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review.

Beta Bionics' estimated fair value has been lifted to about US$21.67 from roughly US$19.80, a revision tied to Wall Street research reassessing the company's pipeline, its expected patch pump entry and the timing of its Type 2 diabetes and fully closed loop indications. Several firms, including Truist, UBS, Leerink and Goldman Sachs, have raised their price targets on the stock, with Truist and UBS pointing to FDA clearance of the Mint patch pump and updated launch timing as key execution milestones as Mint enters the patch pump segment as an alternative to Omnipod. UBS and BofA cited clearer timelines for the Type 2 diabetes and fully closed loop indications, while Truist pointed to survey work suggesting Beta Bionics is gaining share, with iLet screening well for pump naive patients entering the market. Not all research moved in the same direction: Baird and BofA kept Neutral ratings despite higher targets, William Blair initiated at Market Perform and flagged the stock's premium valuation versus Tandem Diabetes, and Ladenburg trimmed its target to US$30.40 from US$32. Behind the fair value change, the model's revenue growth input shifted to about 37.32% from about 35.78%, the net profit margin assumption moved to about 12.58% from about 11.76%, the future P/E assumption adjusted to about 33.33x from about 36.27x, and the discount rate rose to about 7.48% from about 7.38%.

The U.S. Food and Drug Administration on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older, making it the first wearable in the U.S. to continuously monitor ketone levels and the first global system to track blood sugar and ketones simultaneously in a single unit. The agency granted marketing authorization via the De Novo pathway for new low-to-moderate-risk devices, following a review of six clinical studies involving over 600 participants that demonstrated accurate tracking of clinically significant ketone variations. The sensor, which offers up to 10 days of wear, alerts users when ketones rise, replacing single-point urine or blood tests. Abbott is working with pump companies to integrate the sensor with automated insulin delivery systems, expecting compatibility with iLet from Beta Bionics Inc and twiist from Sequel Med Tech by the end of this year, and with systems from Insulet Corp and Tandem Diabetes Care Inc by 2027, alongside an exclusive integration with MiniMedGroup Inc for smart dosing systems. William Blair analyst Brandon Vazquez noted the clearance may create a new competitive dynamic for DexCom Inc shares, with the sensor likely most competitive in the pediatric population once integrated with AID pumps next year.